Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients

doi:10.4254/wjh.v9.i9.469

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9197)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

409

WORD

257

HTML

3518

Figures (1-3)

111

Tables (1-3)

124

Sum=4419

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

439

Download

1185

Sum=1624

Publishing Process of This Article

Item

Count

Browse

1141

Download

2013

Sum=3154

Mar 28, 2017 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Hepatol. Mar 28, 2017; 9(9): 469-476
Published online Mar 28, 2017. doi: 10.4254/wjh.v9.i9.469

Open in New Tab Full Size Figure Download Figure

Figure 1 Box-plot diagram that shows the annexin A2 level in the three groups. HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 2 Box-plot diagram shows the alpha-fetoprotein level in the three groups. AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 3 Receiver operating characteristic curve analysis shows the diagnostic performance of alpha-fetoprotein and annexin A2 in the discrimination of patients with hepatocellular carcinoma from those with chronic liver disease. AFP: Alpha-fetoprotein; NDL: Non-discriminating line (Diagonal line).

Citation: Shaker MK, Abdel Fattah HI, Sabbour GS, Montasser IF, Abdelhakam SM, El Hadidy E, Yousry R, El Dorry AK. Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. World J Hepatol 2017; 9(9): 469-476
URL: https://www.wjgnet.com/1948-5182/full/v9/i9/469.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i9.469